A Queen Elizabeth Hospital King’s Lynn patient, who is currently receiving treatment for COVID-19, has joined a research trial into a range of potential treatments in the fight against the virus.
The patient is the first from QEH to be recruited to the national Recovery Trial, which will include a range of different treatments to establish evidence about which drugs have proven benefits against COVID-19.
The focus of the trial is drugs commonly used to treat HIV (Lopinavir-Ritonavir), inflammation steroids (low-dose Dexamethasone) and anti-malarial drugs (Hydroxychloroquine).
Dr Antonia Hardcastle, Research Lead at the QEH, said: “This is a really important trial, and I am glad we are in the position to offer these novel therapies to our patients in West Norfolk.”
Zoe Coton, Research Nurse, said: “On behalf of the team, we would like to thank everyone for their support in setting up and recruiting our first patient to this ground-breaking trial.”
So far at the QEH, seventy-one patients have tested positive for COVID-19 and 15 of these have been discharged (April 3,2020).
–ENDS—
Pictured: Dr Mohamed Elsaadany, who recruited the first patient. Research and Development Team.
To download the press release and pictures, click here.
QEH Media Hub 